CONTACT-03, 2023 NCT04338269
atezolizumab plus cabozantinib (n=263) vs. cabozantinib (n=259)
randomized controlled trial
atezolizumab plus cabozantinib
atezolizumab (1200 mg intravenously every 3 weeks) plus cabozantinib (60 mg orally once daily)
cabozantinib alone
cabozantinib (60 mg orally once daily) cabozantinib (60 mg orally once daily)
metastatic/advanced RCC (mRCC) - 2nd line (L2)
open-label
135 study sites in 15 countries in Asia, Europe, North America, and South America